Trial Design with Win Statistics for Multiple Time-to-Event Endpoints with Hierarchy

被引:0
|
作者
Barnhart, Huiman X.
Lokhnygina, Yuliya [1 ]
Matsouaka, Roland A. [1 ]
Rockhold, Frank W. [1 ]
机构
[1] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA
关键词
Net benefit; Sample size and power; Win odds; Win ratio; CLINICAL-TRIALS; RATIO;
D O I
10.1080/19466315.2024.2365629
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The conventional approach to the analysis of composite endpoints is time-to-first event analysis. However, this approach has been criticized because it ignores the differences in clinical severity and may end up emphasizing the less severe time-to-event. To overcome this limitation, win statistics (win ratio, win odds, or net benefit) have become popular in analysis of hierarchical time to event endpoints. However, design of randomized clinical trials using the win statistics is lagging behind. In this article, we derive formulas for the win statistics and probability of ties under specific assumptions that can be useful in practice. We also address two design issues: the selection of meaningful and justifiable design parameters and power calculations, when the win statistics method is the primary analysis method for multiple time-to-event endpoints for a pre-specified hierarchy. Finally, we identify patterns where the win statistics approach would have greater statistical power than time-to-first event analysis. Several examples are used to illustrate the usefulness of the formula-based power calculations.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Familywise error for multiple time-to-event endpoints in a group sequential design
    Thomsen, Henrik F.
    Lausvig, Nanna L.
    Pipper, Christian B.
    Andersen, Soren
    Damgaard, Lars H.
    Emerson, Scott S.
    Ravn, Henrik
    [J]. STATISTICS IN MEDICINE, 2024, 43 (18) : 3417 - 3431
  • [2] Adjusted estimates for time-to-event endpoints
    Storer, Barry E.
    Gooley, Ted A.
    Jones, Michael P.
    [J]. LIFETIME DATA ANALYSIS, 2008, 14 (04) : 484 - 495
  • [3] Adjusted estimates for time-to-event endpoints
    Barry E. Storer
    Ted A. Gooley
    Michael P. Jones
    [J]. Lifetime Data Analysis, 2008, 14 : 484 - 495
  • [4] Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpoints
    Capra, WB
    [J]. CONTROLLED CLINICAL TRIALS, 2004, 25 (02): : 168 - 177
  • [5] Time-to-Event Endpoints in Imaging Biomarker Studies
    Chen, Ruizhe
    Wang, Hao
    [J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2024,
  • [6] Reflections on the Win Ratio With Time-to-Event Outcomes
    Wittes, Janet
    [J]. CIRCULATION-HEART FAILURE, 2024, 17 (09)
  • [7] Bayesian design of multi-regional clinical trials with time-to-event endpoints
    Bean, Nathan William
    Ibrahim, Joseph George
    Psioda, Matthew Austin
    [J]. BIOMETRICS, 2023, 79 (04) : 3586 - 3598
  • [8] Bayesian single-arm phase II trial designs with time-to-event endpoints
    Wu, Jianrong
    Pan, Haitao
    Hsu, Chia-Wei
    [J]. PHARMACEUTICAL STATISTICS, 2021, 20 (06) : 1235 - 1248
  • [9] Investigations of methods for multiple time-to-event endpoints: A chronic myeloid leukemia data analysis
    Wu, Hongji
    Hou, Yawen
    Chen, Zheng
    [J]. JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2023, 29 (01) : 211 - 217
  • [10] BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints
    Bi, Dehua
    Liu, Meizi
    Lin, Jianchang
    Liu, Rachael
    [J]. STATISTICS IN MEDICINE, 2023, 42 (30) : 5708 - 5722